Novartis Holds Out For Happier Second Half Of 2021
Sales Inch Up 1% But Cosentyx and Entresto Keep Climbing
Executive Summary
The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.